Phase 3 trial for Secuado® (asenapine) transdermal system demonstrates significant improvement in Positive and Negative Syndrome Scale total score in adults with schizophrenia versus placebo

Secuado is the first-and-only transdermal patch formulation for treatment of adults with schizophrenia approved by the US FDA. In the UK, asenapine is available only as sublingual 5 and 10mg tablets, for bipolar I disorder in adults.

Source:

Biospace Inc.